

**Ohio Department of Medicaid (ODM)
Drug Utilization Review (DUR) Board
Quarterly Meeting
February 6, 2018**

The quarterly meeting of the ODM DUR Board was called to order at 12:12 PM EST in room C621 A&B, 50 West Town Street, Columbus, Ohio. A. Mehran Mostafavifar, M.D. presided.

The following Board members were present:

Robert Kubasak, R.Ph.
Lenard Presutti, D.O.
Michael Dietz, D.O.
A. Mehran Mostafavifar, M.D.
David Brookover, R.Ph.

Also present from ODM were Tracey Archibald, Pharm. D., DUR Administrator, Michelle Barger, Pharm.D., and Donald Wharton, M.D., Assistant Medical Director. Change Healthcare attendees included Benjamin Link, Pharm.D., Jill RK Griffith, Pharm.D., Gail Master, R.Ph., and Katie Fields, Administrative Assistant. Approximately 13 observers were present, most representing pharmaceutical manufacturers.

Roll Call, Reading, Correction, and Approval of previous Minutes

The November 14, 2017, DUR Board Meeting minutes were approved.

DUR Committee Report

G. Master presented a summary on the HIV adherence intervention. The high dose and duplicate therapy of proton pump inhibitors intervention were mailed on 2/1/2018 and a summary of the data was presented. The next intervention will be in March which will identify diabetic patients who are not on an ACE/ARB or statin therapy. Discussion was held around the guidelines of prescribing a statin. G. Master presented an update on the Coordinated Services Program. She informed the Board that per the Department's request, Lyrica, Gabapentin and stimulants will be added to the drug list, and the age criteria will be removed. An outline of the Coordinated Service Program will be sent to the Board. At the next DUR Board meeting, the diabetes letters will be presented.

Health Plan Policy

T. Archibald announced that ODM is accepting electronic Prior Authorization (PA), but indicated that Change Healthcare has not received any yet. Single PDL will begin on July 1, 2018. No changes are expected to the existing PDL excepting the quarterly addition of new drugs. At the P&T Committee meeting held in January 2018, new drugs to market were discussed, and the recommendations were made for these to be non-preferred. T. Archibald announced that prior authorization on compounds exceeding \$100 will be implemented. She informed the Board that beginning January 1, 2018, Medicaid recipients will be enrolled in a Managed Care Plan (MCP) for their first month of coverage rather than starting eligibility in the Fee for Service program. T. Archibald announced that the opening for a pharmacist on the DUR Board is moving forward and that a letter of appointment is in progress.

Unfinished Business

There was no unfinished business.

New Business

G. Master referenced an article from the American Diabetes Association stating the guidelines of adding a statin to a diabetic patient.

G. Master introduced the DUR Digest. This is a new quarterly educational piece directed at prescribers which will review Retro DUR interventions from the previous quarter. The next interventions highlighted will be diabetes and high dose and duplicate stimulants.

Announcements

The dates for the next meetings are Tuesday May 15, Tuesday September 11, and Tuesday November 13, 2018.

Tracey pointed to the Preferred Drug List changes on the DUR Digest, and asked if any Board member would like to receive a notification of these changes.

Adjournment

A. Mehran Mostafavir adjourned the meeting at 12:39 P.M.